Logo image of VKTX

VIKING THERAPEUTICS INC (VKTX) Stock Overview

USA - NASDAQ:VKTX - US92686J1060 - Common Stock

31.42 USD
-1.56 (-4.73%)
Last: 10/22/2025, 7:43:47 PM
32.25 USD
+0.83 (+2.64%)
After Hours: 10/22/2025, 7:43:47 PM

VKTX Key Statistics, Chart & Performance

Key Statistics
Market Cap3.53B
Revenue(TTM)N/A
Net Income(TTM)-171547000
Shares112.44M
Float109.65M
52 Week High81.73
52 Week Low18.92
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.53
PEN/A
Fwd PEN/A
Earnings (Next)10-22 2025-10-22/amc
IPO2015-04-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


VKTX short term performance overview.The bars show the price performance of VKTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

VKTX long term performance overview.The bars show the price performance of VKTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 200 400 600

The current stock price of VKTX is 31.42 USD. In the past month the price increased by 17.99%. In the past year, price decreased by -59.73%.

VIKING THERAPEUTICS INC / VKTX Daily stock chart

VKTX Latest News, Press Relases and Analysis

VKTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.59 403.98B
AMGN AMGEN INC 13.57 159.34B
GILD GILEAD SCIENCES INC 15.69 150.71B
VRTX VERTEX PHARMACEUTICALS INC 25.17 109.33B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.94B
REGN REGENERON PHARMACEUTICALS 12.81 61.98B
ARGX ARGENX SE - ADR 88.4 50.13B
INSM INSMED INC N/A 33.90B
ONC BEONE MEDICINES LTD-ADR 5.06 34.44B
BNTX BIONTECH SE-ADR N/A 25.54B
NTRA NATERA INC N/A 25.81B
BIIB BIOGEN INC 9.23 21.66B

About VKTX

Company Profile

VKTX logo image Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 48 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.

Company Info

VIKING THERAPEUTICS INC

9920 Pacific Heights Blvd, Suite 350

San Diego CALIFORNIA 92130 US

CEO: Brian Lian

Employees: 48

VKTX Company Website

VKTX Investor Relations

Phone: 18587044660

VIKING THERAPEUTICS INC / VKTX FAQ

What is the stock price of VIKING THERAPEUTICS INC today?

The current stock price of VKTX is 31.42 USD. The price decreased by -4.73% in the last trading session.


What is the ticker symbol for VIKING THERAPEUTICS INC stock?

The exchange symbol of VIKING THERAPEUTICS INC is VKTX and it is listed on the Nasdaq exchange.


On which exchange is VKTX stock listed?

VKTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VIKING THERAPEUTICS INC stock?

23 analysts have analysed VKTX and the average price target is 95.81 USD. This implies a price increase of 204.94% is expected in the next year compared to the current price of 31.42. Check the VIKING THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VIKING THERAPEUTICS INC worth?

VIKING THERAPEUTICS INC (VKTX) has a market capitalization of 3.53B USD. This makes VKTX a Mid Cap stock.


How many employees does VIKING THERAPEUTICS INC have?

VIKING THERAPEUTICS INC (VKTX) currently has 48 employees.


What are the support and resistance levels for VIKING THERAPEUTICS INC (VKTX) stock?

VIKING THERAPEUTICS INC (VKTX) has a support level at 31.41 and a resistance level at 33.57. Check the full technical report for a detailed analysis of VKTX support and resistance levels.


Should I buy VIKING THERAPEUTICS INC (VKTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VIKING THERAPEUTICS INC (VKTX) stock pay dividends?

VKTX does not pay a dividend.


When does VIKING THERAPEUTICS INC (VKTX) report earnings?

VIKING THERAPEUTICS INC (VKTX) will report earnings on 2025-10-22, after the market close.


What is the Price/Earnings (PE) ratio of VIKING THERAPEUTICS INC (VKTX)?

VIKING THERAPEUTICS INC (VKTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.53).


What is the Short Interest ratio of VIKING THERAPEUTICS INC (VKTX) stock?

The outstanding short interest for VIKING THERAPEUTICS INC (VKTX) is 24.63% of its float. Check the ownership tab for more information on the VKTX short interest.


VKTX Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to VKTX. When comparing the yearly performance of all stocks, VKTX is a bad performer in the overall market: 93.29% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VKTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VKTX. VKTX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VKTX Financial Highlights

Over the last trailing twelve months VKTX reported a non-GAAP Earnings per Share(EPS) of -1.53. The EPS decreased by -62.77% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -20.72%
ROE -21.57%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-190%
Sales Q2Q%N/A
EPS 1Y (TTM)-62.77%
Revenue 1Y (TTM)N/A

VKTX Forecast & Estimates

23 analysts have analysed VKTX and the average price target is 95.81 USD. This implies a price increase of 204.94% is expected in the next year compared to the current price of 31.42.


Analysts
Analysts86.09
Price Target95.81 (204.93%)
EPS Next Y-147.07%
Revenue Next YearN/A

VKTX Ownership

Ownership
Inst Owners67.53%
Ins Owners2.15%
Short Float %24.63%
Short Ratio3.92